61 Tiotropium Respimat in cystic fibrosis: Efficacy and safety results of phase III randomized placebo-controlled trial  by Ratjen, F. et al.
S64 4. New therapies Posters
61 Tiotropium Respimat in cystic ﬁbrosis: Efﬁcacy and safety results
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F. Ratjen1, P. Koker2, D. Geller3, B. Langellier-Cocteaux4, F. Le Maulf4,
S. Kattenbeck5, P. Moroni-Zentgraf6, J.S. Elborn7. 1The Hospital of Sick Children,
Toronto, Canada; 2Boehringer Ingelheim Pharmaceuticals Inc., Ridgeﬁeld, United
States; 3Florida State University College of Medicine, Orlando, United States;
4Boehringer Ingelheim France SAS, Reims, France; 5Boehringer Ingelheim
Pharma GmbH & Co KG, Ingelheim, Germany; 6Boehringer Ingelheim GmbH,
Ingelheim, Germany; 7Queen’s University Belfast, Centre for Infection and
Immunity, Belfast, N Ireland, United Kingdom
Background: Tiotropium, a once-daily (qd), long-acting, anticholinergic bron-
chodilator delivered via Respimat® Soft Mist™ Inhaler, signiﬁcantly improved lung
function in a phase II trial investigating two doses (2.5 and 5 mg qd) in people
with cystic ﬁbrosis (CF). Lung function improved dose-dependently and safety was
balanced overall, supporting further investigation of the 5mg dose in a phase III
trial.
Methods: This phase III, 12-week, randomized, double-blind, placebo-controlled,
parallel-group trial of tiotropium 5mg via Respimat® followed by an open-label,
active-treatment phase (>12 weeks) included people with CF and prebronchodilator
FEV1 25%pred normal (no upper limit). All usual CF maintenance therapies were
allowed throughout the trial.
Results: During the double-blind period, 463 patients (tiotropium 308, placebo 155;
mean age 19.8 y) were treated. Differences between tiotropium vs placebo in change
from baseline at Week 12 in both coprimary efﬁcacy endpoints were not statistically
signiﬁcant: %pred FEV1 AUC0−4h, 1.64%, 95%CI −0.27, 3.55, P= 0.092; %pred
trough FEV1, 1.40%; 95%CI −0.50, 3.30; P= 0.15. The proportion of patients with
1 pulmonary exacerbation (per RSSQ method: tiotropium 8.9%, placebo 7.8%)
and changes in CFQ-R mean domain scores were similar in both treatment groups
over 12 weeks. Adverse events (AEs) were similar in both groups with relevant
AEs mainly related to pulmonary exacerbations.
Conclusion: Lung function improvement in patients on tiotropium vs placebo as
add-on to CF standard of care was not statistically signiﬁcant. Tiotropium was well
tolerated in people with CF, consistent with the known safety proﬁle of tiotropium
in COPD.
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Objectives: The need for effective, non-invasive treatment for Cystic Fibrosis (CF)
growth failure is imperative, as lung function scores closely track weight percentile
in CF.
Methods: We perform an age-stratiﬁed, placebo-controlled, double-blinded, re-
peated measures clinical trial of oral GSH in 44 pediatric CF patients over six
months (dose 65mg/kg, divided into three doses per day).
Conclusion: The GSH treatment group gained an average of 16.9 weight percentile
points over the course of six months, with no adverse side effects (versus placebo
+2.9, p< 0.001), representing almost a doubling of their mean weight percentile
at baseline. Other measures, including fecal calprotectin, height percentile, BMI,
FEV1% and FVC%, also improved signiﬁcantly in the GSH treatment group.
Glutahione is a ubiquitous tripeptide, found in all mammalian tissue. Glutathione
is present in nearly all foods, and a normal diet would provide approximately 100–
250mg per day. Oral GSH has no known toxicity.
There is a pressing need for safe, effective, and non-invasive techniques to augment
weight gain in children with cystic ﬁbrosis. Cochrane Database reviews of current
weight augmentation treatments in pediatric cystic ﬁbrosis patients found that high
calorie oral supplements were non-effective; enteral tube feeding was minimally
effective and invasive with negative side effects; and appetite stimulants were
marginally effective with signiﬁcant negative side effects.
Given the favorable safety proﬁle of oral GSH, we recommend that clinicians
consider whether their patients might beneﬁt from the addition of oral GSH to
their daily regimen.
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Background: Ataluren, which enables readthrough of premature termination codons
and production of full-length protein in individuals with nonsense mutations (nm), is
being developed as a potential therapy in CF. CT scan scores were used to measure
the effects of ataluren on lung disease in nmCF.
Methods: This Phase 3, double-blind study enrolled patients 6 yrs of age with
nmCF to receive daily TID ataluren 10, 10, 20mg/kg or placebo (PBO) for 48 wks.
A CT scan of the chest was obtained at baseline and at end of treatment (EOT).
Each lobe was scored using the Brody scoring system. The average of 2 blinded
reviewers was used to determine total lung score (TLS) and speciﬁc subscores
(lower scores indicating improvement).
Results: Baseline and EOT CT scans were obtained for 203 patients who completed
48 wks of blinded treatment. The difference in mean TLS between the ataluren and
PBO groups at EOT (−0.28) was not signiﬁcant. The mean change from baseline
in TLS at EOT was small for the ataluren group (0.28±1.34; n = 99) and the PBO
group (0.56±1.56; n = 104) and was not signiﬁcant. Importantly, this lack of change
in the PBO group is contrasted to the mean relative change in %-pred FEV1 of
−5.5% seen during the same time period.
Conclusion: This double-blind study represents the largest study using CT scans
to measure the effects of a therapeutic intervention. The lack of change in TLS in
the PBO arm, despite a signiﬁcant reduction in FEV1 over 48 wks, suggests that
morphologic change on CT does not parallel functional change in FEV1. That the
lack of disease progression as observed on CT may limit its use in study designs
dependent on progressive disease in the PBO arm.
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Background: Tiotropium is a once-daily, long-acting, anticholinergic bronchodila-
tor. Tiotropium Respimat® Soft Mist™ Inhaler improved lung function compared
with placebo as add-on treatment to standard of care in phase II (Elborn et al.
J Cystic Fibrosis. 2011;10;Suppl 1;S21/A080) and III trials in people with cystic
ﬁbrosis (CF), but statistical signiﬁcance was only reached in the phase II trial. A
prespeciﬁed pooled analysis was conducted to increase the precision of the estimates
on the efﬁcacy and safety of tiotropium 5 mg in CF.
Methods: The randomized, double-blind, 12-week clinical, phase II and III trials
followed the same design to enable pooling. People with CF with a prebron-
chodilator FEV1 25%pred normal (no upper limit) were included. All usual CF
maintenance therapies were allowed throughout the trial.
Results: A total of 807 patients (323 placebo; 484 tiotropium) were treated (mean
age 20.1 y). A treatment difference in favour of tiotropium was observed in the
change from baseline %pred FEV1 AUC0−4h (2.62%; 95% CI 1.34, 3.90) and
%pred trough FEV1 (1.85%; 95% CI 0.53, 3.18). The proportion of patients with
1 pulmonary exacerbation (per RSSQ method tiotropium 7.5%; placebo: 8.6%)
and changes in mean domain scores of the CFQ-R were similar between treatment
groups. Adverse events (AEs) were similar in both groups with relevant AEs mainly
related to pulmonary exacerbations.
Conclusion: In people with CF, the bronchodilatory effects of tiotropium were
not accompanied by improvements in symptomatic and health outcome parameters.
Tiotropium was well tolerated in people with CF, consistent with the known safety
proﬁle of tiotropium in COPD.
